(19) Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number: **0 382 762 B1**

(12) EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification: **15.12.93** (51) Int. Cl.5: **C12N 15/00**, C12N 9/08

(21) Application number: **88908734.2**

(22) Date of filing: **07.10.88**

(86) International application number:
PCT/GB88/00833

(87) International publication number:
WO 89/03424 (20.04.89 89/09)

(54) SYNTHETIC GENE.

(30) Priority: **08.10.87 GB 8723662**

(43) Date of publication of application:
22.08.90 Bulletin 90/34

(45) Publication of the grant of the patent:
15.12.93 Bulletin 93/50

(84) Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

(56) References cited:
EP-A- 0 068 375
EP-A- 0 171 024

EUROPEAN JOURNAL OF BIOCHEMISTRY,vol. 96, 1979, Springer-Verlag,(Berlin, DE), K.G. Welinder: "Amino acid sequence studies of horseradish peroxidase. Amino and carboxyl termini, cyanogen bromide and tryptic fragments, the complete sequence, and some structural characteristics of horseradish peroxidase C", pp. 483-502

(73) Proprietor: **BRITISH BIO-TECHNOLOGY LIMITED**
Watlington Road
Cowley Oxford OX4 5LY(GB)

(72) Inventor: **EDWARDS, Richard, Mark**
7 Ludlow Drive
Thame
Oxon(GB)
Inventor: **BURKE, Julian, Francis**
6 Friar's Walk
Lewes
East Sussex BN7 2LE(GB)

(74) Representative: **Sheard, Andrew Gregory et al**
Kilburn & Strode
30, John Street
London WC1N 2DD (GB)

Rank Xerox (UK) Business Services
(3.10/3.6/3.3.1)

Description

This invention relates to synthetic genes coding for horseradish peroxidase.

Horseradish peroxidase C (E.C.1.11.1.7) (HRP) is the major peroxidase isozyme isolated from the horseradish (Armoracia rusticana). It is a monomeric glycoprotein of 308 amino acids the polypeptide chain having a MW of 33,980 D. There are three neutral carbohydrate side chains and 4 disulphide bridges. The amino acid sequence of the mature protein has been determined. The presence of a pyrrolidonecarboxylyl amino terminus indicates that the protein is probably produced as a precursor form that is processed on secretion. The active form of the enzyme contains a hemin prosthetic group.

The enzyme is particularly stable and is amenable to crosslinking and derivitisation without excessive loss of activity. This together with its wide range of chromogenic substrates, some of which give rise to insoluble, chemiluminescent or fluorescent products, and the low background activities observed in most applications, have made horseradish peroxidase an invaluable tool for diagnostic and research applications in the fields of immunology, histochemistry, cytology and molecular biology. A further advantage it presents over other enzymatic markers is that some some substrates for the enzyme give rise to electron dense products that allow correlation of peroxidase location with cellular ultrastructure using electron microscopy. In addition, horseradish peroxidase is electron dense itself by virtue of the Fe it contains and as a result can act as an E.M. marker in its own right. Particular applications have been found in immunochemistry, where peroxidase cross linked to immunoglobulin is widely used in both ELISA based assay systems and immunocytochemistry. Methods have been described that use either direct crosslinking of peroxidase to the immunoglobulin or indirect crosslinking of biotin labelled immunoglobulin to a streptavidin/horseradish peroxidase complex. Such streptavidin complexes have also found widespread application in nucleic acid hybridisation methods where biotinylated probe sequences can be localised by sequential incubation with the streptavidin/peroxidase complex and a suitable chromogenic peroxidase substrate.

The amino acid sequence of horseradish peroxidase is taught by Welinder, K.G. (Eur. J. Biochem. **96**, 483-502 (1979)). The cloning of the cDNA or natural gene for horseradish peroxidase has not been described.

In order to facilitate the dissection of the structure/function relationships of HRP, its incorporation into expression vectors and the production of novel chimeric proteins containing HRP functionality an improved novel synthetic gene for the peroxidase C produced by Armoracia rusticana is sought.

It is by no means easy to predict the design of an improved HRP gene, since the factors that determine the expressibility of a given DNA sequence are still poorly understood. Furthermore, the utility of the gene in various applications will be influenced by such considerations as codon usage and restriction sites. The present invention relates to a synthetic HRP gene which has advantages in the ease with which it can be modified due to the presence of useful restriction sites.

When synthesising and assembling genes, problems have been encountered when there are inverted or direct repeats greater than eight bases long in the genetic sequence. In addition, areas of unbalanced base composition such as G/C or A/T rich regions or polypurine/polypyrimidine tracts have been found to lead to inefficient expression. The present invention seeks to overcome or at least alleviate these difficulties.

According to a first aspect of the invention, there is provided DNA coding for horseradish peroxidase and including the following sequence:

```
CAG TTA ACC CCT ACA TTC TAC GAC AAT AGC TGT CCC
AAC GTG TCC AAC ATC GTT CGC GAC ACA ATC GTC AAC
GAG CTC AGA TCC GAT CCC AGG ATC GCT GCT TCA ATA
TTA CGT CTG CAC TTC CAT GAC TGC TTC GTG AAT GGT
TGC GAC GCT AGC ATA TTA CTG GAC AAC ACC ACC AGT
TTC CGC ACT GAA AAG GAT GCA TTC GGG AAC GCT AAC
AGC GCC AGG GGC TTT CCA GTG ATC GAT CGC ATG AAG
GCT GCC GTT GAG TCA GCA TGC CCA CGA ACA GTC AGT
TGT GCA GAC CTG CTG ACT ATA GCT GCG CAA CAG AGC
```

GTG ACT CTT GCA GGC GGA CCG TCC TGG AGA GTG CCG
CTC GGT CGA CGT GAC TCC CTA CAG GCA TTC CTA GAT
CTG GCC AAC GCC AAC TTG CCT GCT CCA TTC TTC ACC
CTG CCC CAG CTG AAG GAT AGC TTT AGA AAC GTG GGT
CTG AAT CGC TCG AGT GAC CTT GTG GCT CTG TCC GGA
GGA CAC ACA TTT GGA AAG AAC CAG TGT AGG TTC ATC
ATG GAT AGG CTC TAC AAT TTC AGC AAC ACT GGG TTA
CCT GAC CCC ACG CTG AAC ACT ACG TAT CTC CAG ACA
CTG AGA GGC TTG TGC CCA CTG AAT GGC AAC CTC AGT
GCA CTA GTG GAC TTT GAT CTG CGG ACC CCA ACC ATC
TTC GAT AAC AAG TAC TAT GTG AAT CTA GAG GAG CAG
AAA GGC CTG ATA CAG AGT GAT CAA GAA CTG TTT AGC
AGT CCA AAC GCC ACT GAC ACC ATC CCA CTG GTG AGA
AGT TTT GCT AAC TCT ACT CAA ACC TTC TTT AAC GCC
TTC GTG GAA GCC ATG GAC CGT ATG GGT AAC ATT ACC
CCT CTG ACG GGT ACC CAA GGC CAG ATT CGT CTG AAC
TGC AGA GTG GTC AAC AGC AAC TCT

The above sequence may be immediately preceded by an initiation codon (ATG) and immediately followed by a termination codon (TAA), but this will not necessarily be the case if the DNA incorporates linker(s) and/or extension(s), such as a sequence coding for a signal peptide, for example for efficient expression in eukaryotic cells such as mammalian cells. One extension which gives good expression in mammalian cells is a 5'-extension coding for the amino acids KCSWVIFFLMAVVTGVNS, which may be provided between an initiation codon and the codon coding for the first Q residue. A preferred such extension is shown in Figure 6. A sequence coding for a 3'-signal sequence may code for LLHDMVEVVDFVSSM; a preferred DNA sequence coding for this series of amino acid residues is also shown in Figure 6. Other useful 5' extensions are AAGCTTAACCATG and AAGCTTCATATG and a useful 3' extension is TAATAAGGATCCGAATTC.

A synthetic HRP gene as described above incorporates useful restriction sites at frequent intervals to facilitate the cassette mutagenesis of selected regions. Also included in preferred embodiments are flanking restriction sites to simplify the incorporation of the gene into any desired expression system.

Codons are those that are favoured by E. coli but it is expected that the DNA would be suitable for expression in other organisms including yeast and mammalian cells.

According to a second aspect of the invention, there is provided a genetic construct comprising DNA according to the first aspect. A genetic construct in accordance with the second aspect may be a vector, such as a plasmid, cosmid or phage.

According to a third aspect of the invention, there is provided a process for the preparation of DNA in accordance with the first aspect or a genetic construct in accordance with the second aspect, the process comprising coupling successive nucleotides and/or ligating appropriate oligomers.

The invention also relates to other nucleic acid (including RNA) either corresponding to or complementary to DNA in accordance with the first aspect.

The invention encompasses a process for the production of monodisperse horseradish peroxidase C comprising the expression of a genetic construct as described above.

Further, the invention extends to constructs as described above comprising a sequence in accordance with the first aspect fused to any other sequence of DNA so as to result in a sequence capable of encoding a hybrid protein possessing peroxidase activity. An example of such a construct is a genetic fusion between a gene encoding horseradish peroxidase and a gene encoding streptavidin or avidin such that the encoded fusion protein possesses both biotin binding and peroxidase activity. Another example is a genetic fusion between a gene encoding horseradish peroxidase and a gene encoding an immunoglobulin-derived antigen

binding function such that the fusion protein possesses both antigen binding and horseradish peroxidase activity. The antigen binding function may be an immunoglobulin heavy chain or light chain or fragments thereof or an engineered monomeric antigenic recognition site.

Particular constructs of interest include: vectors comprising the gene for horseradish peroxidase C that enable the production of fusions between horseradish peroxidase and any other protein of interest; and expression vectors that provide for the co-expression of the gene for horseradish peroxidase and another gene of interest either as a single fusion product, as a single polycistronic message or as two separate but linked transcriptional units.

According to a further aspect of the invention, there is provided a gene for horseradish peroxidase containing a mutation (either missense, nonsense, deletion, insertion, duplication or other re-arrangement) that destroys or impairs the activity of the encoded horseradish peroxidase protein. The invention extends to genetic constructs including all or a fragment of such a mutant horseradish peroxidase gene.

Defective or non-defective horseradish peroxidase genetic constructas can be employed (for example as markers) in mammalian cells and/or in transgenic animals.

Specific applications of synthetic genes for horseradish peroxidase, which themselves form further aspects of the invention, are disclosed in greater detail below:

1) The gene can be incorporated into a suitable expression vector to allow for the efficient production of the enzyme in a compatible organism. This will have the advantage of being a ready source of a monodisperse enzyme preparation free of the contaminating isozymes present in the material isolated from horseradish root. Varying the organism or cell type chosen for production will also allow for the production of HRP with different patterns of glycosylation, including no glycosylation. Such material will have better defined properties that will make it more suitable for more demanding histochemical applications and sensitive enzyme assays, especially immunoassays.

2) The gene can be incorporated into an HRP-streptavidin or HRP-avidin gene fusion. This will allow for the production of streptavidin-HRP or avidin-HRP complexes without the need for cross-linking. Again this will allow for a better defined, more stable product and will probably result in less loss of both biotin binding and peroxidase activity.

3) Similarly, fusions between immunoglobulins and HRP or protein A and HRP can be produced that would be valuable histochemical reagents. Again the need for the usual cross-linking procedures would be avoided.

4) The HRP gene would have valuable applications in the construction of vectors designed to allow the production of fusions between HRP and any other protein for which a gene or cDNA had been cloned or for which the amino acid sequence is known. This would be useful both for monitoring the expression of a gene the product of which is difficult to assay and to tag the protein of interest to allow its metabolism and pharmodynamics to be followed in vivo by the use of the appropriate histochemical techniques or enzyme assays. Additionally, HRP fusions will allow for a simple immunopurification of the fusion product through the use of an appropriate anti-HRP antibody.

5) The expression of HRP will be a useful marker in expression systems, eg mammalian cell expression systems. The HRP gene could be expressed either as a fusion or on a polycistronic message with the gene of interest, or as a separate but closely linked transcriptional unit. The production of the easily assayed HRP could be readily screened for and used as an indication as to which clones of cells were likely to be expressing large quantities of the deisred product. The use of fluorescent or chemiluminescent HRP chromogenic substrates would allow for the possibility of directly selecting high producing eukaryotic cells by fluorescence activated cell-sorting (FACS).

6) HRP genes carrying mutations (missense, nonsense, deletion, insertion, duplication or other re-arrangement) that destroy or impair the enzymatic activity of the resultant product would allow the construction of vectors that could be used to follow the frequency of reversion or suppression of the particular mutation introduced into the gene.

The introduction of such defective HRP genes into the germ line of the organism of interest would also enable a researcher to fate-map particular cell-types by histologically examining the pattern of HRP activity in the tissue of interest. Care would have to be excercised in constructing a mutant HRP gene with the correct in vivo reversion rate so that areas of HRP activity and hence the presence of reverted HRP gene could be taken as evidence for the clonal origin of the HRP + cells. The intact synthetic non-mutant gene could also be used for such fate-mapping experiments by infection of an organism with the HRP gene in a siutable vector such as a retroviral vector or transposon.

7) The advantage of a synthetic gene for HRP allows for the production of HRP genes modified to encode a protein carrying small additional sequences, such as N-or C- terminal extensions. These will be of great application in simplifying the purification of the HRP and/or increasing the ease and enhancing

the specificity with which it can be cross-linked to other proteins of interest or otherwise derivatised. For example, a C-terminal extension of six to eight Arg residues could be used to simplify purification by analogy with the technique of Sassenfeld et al. Bio/technology **2** 76 (1984). Alternatively, a tail of Lys residues would provide an accessible and sensitive site for reaction with bifunctional cross-linking reagents such as glutaraldehyde.

Preferred embodiments and examples of the invention will now be described. In the following description, reference is made to a number of drawings, in which:

Figure 1 shows the amino acid sequence of horseradish peroxidase C;

Figure 2 shows the sequence of the horseradish peroxidase synthetic gene; a summary of useful restriction sites; and a sequence of front and back halves of the gene that were initially cloned;

Figure 3 shows a sequence of synthetic horseradish peroxidase gene divided into oligonucleotides;

Figure 4 shows a summary of assembly procedure used;

Figure 5 shows the structure of the HRP E. coli expression plasmid pSD18;

Figure 6 shows a synthetic HRP gene modified for efficient expression in mammalian cells; and

Figure 7 shows the structure of the HRP mammalian expression plasmid pCP21.

Example 1

The gene was designed to be synthesized and cloned, in this example, in two halves with a final sub-cloning step to yield the full length gene. The sequence of the two halves of the gene together with that of the final product are depicted in Figure 2. The final synthetic gene encodes the entire mature horseradish peroxidase protein together with the required initiator methionine residue but lacks the leader sequence that is assumed to be present in the natural gene. It is envisaged that the leader sequence appropriate to the expression system of choice would be added to the synthetic gene as required or ommitted to allow for intracellular expression of the gene.

The desired gene sequence was divided into a front half and a back half of 501 and 474 bp respectively. Both halves were designed with a common XhoI site to allow for the complete gene to be assembled with a simple cloning step. The front and back halves of the gene were divided into 24 and 22 oligodeoxyribonucleotides (oligomers) respectively as depicted in Figure 3. The division was such as to provide 7 base cohesive ends after annealing complementary pairs of oligomers. The end points of the oligomers were chosen to minimize the potential for inappropriate ligation of oligomers at the assembly stage.

The oligomers were synthesized by automated solid phase phosphoramidite chemistry. Following de-blocking and removal from the controlled pore glass support the oligomers were purified on denaturing polyacrylamide gels, further purified by ethanol precipitation and finally dissolved in water prior to estimation of their concentration.

All the oligomers with the exception of the 5' terminal oligomers BB279 and BB302 for the front half and BB303 and BB324 for the back half were then kinased to provide them with a 5' phosphate as required for the ligation step. Complementary oligomers were then annealed and the oligomers ligated together by T4 DNA ligase as depicted in Figure 4. The ligation products were separated on a 2% low gelling temperature (LGT) gel and the bands corresponding to the front and back halves of the horseradish peroxidase gene were cut out and extracted from the gel. The purified fragments were then ligated separately to EcoRI/HindIII cut DNA of the plasmid vector pUC18. The ligated products were transformed into HW87 and plated on L-agar plates containing 100 mcg ml^{-1} ampicillin. Colonies containing potential clones were then grown up in L-broth containing ampicillin at 100 mcg ml^{-1} and plazmid DNA isolated. Positive clones were identified by direct dideoxy sequence analysis of the plasmid DNA using the 17 base universal primer, a reverse sequencing primer complementary to the opposite strand on the other side of the polylinker and some of the oligomers employed in the assembly of the gene that served as internal primers. One front half and one back half clone were subsequently re-sequenced on both strands to confirm that no mutations were present. The complete gene was then assembled by isolating the 466 bp XhoI-EcoRI fragment from the back half calone that contained the 3' end of the gene and ligating it to a front half clone that had also been digested with EcoRI and XhoI. The identity of the final construct was confirmed by restriction analysis and subsequent complete resequencing.

All the techniques of genetic manipulation used in the manufacture of this gene are well known to those skilled in the art of genetic engineering. A description of most of the techniques can be found in one of the following laboratory manuals: Molecular Cloning by T. Maniatis, E.F. Fritsch and J. Sambrook published by Cold Spring Harbor Laboratory, Box 100, New York, USA, or Basic Methods in Molecular Biology by L.G.

Davis, M.D. Dibner and J.F. Battey published by Elsevier Science publishing Co. Inc. New York, USA.

Additional and modified methodologies are detailed below.

1) Oligonucleotide synthesis

The oligonucleotides were synthesized by automated phosphoramidite chemistry using cyanoethyl phosphoramidtes. The methodology is now widely used and has been described (Beaucage, S.L. and Caruthers, M.H. Tetrahedron Letters. **24**, 245 (1981)).

2) Purification of Oligonucleotides

The oligonucleotides were de-protected and removed from the CPG support by incubation in concentrated NH3. Typically, 50 mg of CPG carrying 1 micromole of oligonucleotide was de-protected by incubation for 5 hr at 70° in 600 mcl of concentrated NH_3. The supernatant was transferred to a fresh tube and the oligomer precipitated with 3 volumes of ethanol. Following centrifugation the pellet was dried and resuspended in 1 ml of water. The concentration of crude oligomer was then determined by measuring the absorbance at 260 nm.

For gel purification 10 absorbance units of the crude oligonucleotide were dried down and resuspended in 15 mcl of marker dye (90% de-ionised formamide, 10mM tris, 10 mM borate, 1mM EDTA, 0.1% bromophenol blue). The samples were heated at 90° for 1 minute and then loaded onto a 1.2 mm thick denaturing polyacrylamide gel with 1.6 mm wide slots. The gel was prepared from a stock of 15% acrylamide, 0.6% bisacrylamide and 7M urea in 1 X TBE and was polymerised with 0.1% ammonium persulphate and 0.025% TEMED. The gel was pre-run for 1 hr. The samples were run at 1500 V for 4-5 hr. The bands were visualized by UV shadowing and those corresponding to the full length product cut out and transferred to micro-testubes. The oligomers were eluted from the gel slice by soaking in AGEB (0.5 M ammonium acetate, 0.01 M magnesium acetate and 0.1 % SDS) overnight. The AGEB buffer was then transferred to fresh tubes and the oligomer precipitated with three volumes of ethanol at -70° for 15 min. The precipitate was collected by centrifugation in an Eppendorf microfuge for 10 min, the pellet washed in 80 % ethanol, the purified oligomer dried, redissolved in 1 ml of water and finally filtered through a 0.45 micron micro-filter. The concentration of purified product was measured by determining its absorbance at 260 nm.

3) Kinasing of oligomers

250 pmole of oligomer was dried down and resuspended in 20 mcl kinase buffer (70 mM Tris pH 7.6, 10 mM MgCl2, 1 mM ATP, 0.2 mM spermidine, 0.5 mM dithiothreitol). 10 u of T4 polynucleotide kinase was added and the mixture incubated at 37° for 30 min. The kinase was then inactivated by haeating at 85° for 15 min.

4) Annealing

8 mcl of each oligomer was mixed, heated to 90° and then slow cooled to room temperature over a period of an hour.

5) Ligation

5 mcl of each annealed pair of oligomers were mixed and 10 X ligase buffer added to give a final ligase reaction mixture (50 mM Tris pH 7.5, 10 mM $MgCl_2$, 20 mM dithiothreitol, 1 mM ATP. T4 DNA ligase was added at a rate of 100 u per 50 mcl reaction and ligation carried out at 15° for 4 hr.

6) Agarose gel electrophoresis

Ligation products were separated using 2% low gelling temperature agarose gels in 1 X TBE buffer (0.094 M Tris pH8.3, 0.089 M boric acid, 0.25 mM EDTA) containing 0.5 mcg ml^{-1} ethidium bromide.

7) Isolation of ligation products

The band corresponding to the expected horseradish peroxidase gene or gene fragment ligation product was identified by reference to size markers under long wave UV illumination. The band was cut out of the gel and the DNA extracted as follows.

The volume of the gel slice was estimated from its weight and then melted by incubation at 65° for 10 min. The volume of the slice was then made up to 400 mcl with TE (10 mM Tris pH 8.0, 1 mM EDTA) and Na acetate added to a final concentration of 0.3 M. 10 mcg of yeast tRNA was also added as a carrier. The DNA was then subjected to three rounds of extraction with equal volumes of TE equilibrated phenol followed by three extractions with ether that had been saturated with water. The DNA was precipitated with 2 volumes of ethanol, centrifuged for 10 min in a microfuge, the pellet washed in 70 % ethanol and finally dried down. The DNA was taken up in 20 mcl of TE and 2 mcl run on a 2 % agarose gel to estimate the recovery of DNA.

8) Cloning of fragments

For the initial cloning of the two halves of horseradish peroxidase 0.5 mcg of pUC18 DNA was prepared by cleavage with HindIII and EcoRI as advised by the suppliers. The digested DNA was run on an 0.8 % LGT gel and the vector band purified as described above. For the final assembly step the clone carrying the front half of the horseradish peroxidase gene was treated similarly using the enzymes XhoI and EcoRI.

20 ng of cut vector DNA was then ligated to various peroxidase gene DNA ranging from 2 to 20 ng for 4 hr using the ligation buffer described above. The ligation products were used to transform competent HW87 as has been described. Ampicillin resistant transformants were selected on L-agar plates containing 100 mcg ml^{-1} ampicillin.

9) Isolation of plasmid DNA

Plasmid DNA was prepared from the colonies containing potential horseradish peroxidase clones essentially as described (Ish-Horowicz, D., Burke, J.F. Nucleic Acids Research **9** 2989-2998 (1981).

10) Dideoxy sequencing

The protocol used was essentially as has been described (Biggin, M.D., Gibson, T.J., Hong, G.F. P.N.A.S. **80** 3963-3965 (1983)). The method was modified to allow sequencing on plasmid DNA as described (Guo, L-H., Wu, R. Nucleic Acids Research 11 5521-5540 (1983).

11) Transformation

Transformation was accomplished using standard procedures. The strain used as a recipient in the cloning was HW87 which has the following genotype:
araD139(ara-leu)del7697 (lacIPOZY)del74 galU galK hsdR rpsL srl recA56
Any other standard cloning recipient such as HB101 would be adequate.

Example 2

The front end of the synthetic HRP gene prepared in Example 1 was modified by the replacement of the HindIII-HpaI fragment with a synthetic linker carrying an NdeI site on the initiator ATG as follows:

```
            M  Q  L  T  .  .  .
AAGCTTCATATGCAGTTAACC.........
HindIII NdeI  HpaI
```

Example 3

Expression of the Synthetic horseradish peroxidase Gene in Escherichia coli

The synthetic HRP gene of Example 2 was cloned into the expression vector pGC517 on a NdeI-BamHI fragment to give the plasmid pSD18. The host vector pGC517 was prepared from the known plasmid pAT153 (Twigg & Sherratt Nature **283**, 216-218 (1980)), which is now a standard E. coli high expression vector, by the incorporation by standard methods of the known tac promoter sequence and a termination sequence. pAT153 is itself a derivative of pBR322. In pGC517 the HRP gene is expressed from the powerful and regulatable tac promoter. To ensure that expression remained repressed in uninduced cultures the plasmid was maintained in E. coli strain W3110 $lacI^q$, which is widely available, in which the lac repressor protein is over-produced. Figure 5 depicts the structure of pSD18.

Strain W3110 $lacI^q$-pSD18 was grown in M9 minimal medium containing 0.2% glucose and 0.2% casamino acids. At an O.D. of 0.2 - 0.3 the culture was induced by the addition of IPTG to a final concentration of 5mM. The culture was grown for a further 3 hr with samples removed at 30 min intervals.

Microscopic examination of the induced culture revealed the presence of inclusion bodies, characteristic of the accumulation of large amounts of insoluble aggregated protein within the cell. In addition, cultures expressing HRP at high levels acquired a pink colouration, perhaps related to the overexpression of a haem protein. SDS/PAGE analysis subsequently revealed the presence of a large amount of a 33 kD protein, estimated at 10-20% of total cell protein in induced but not uninduced cultures. Western blot analysis confirmed that this protein was HRP.

Standard methods for inclusion body isolation could be applied to obtain a substantial purification of the denatured HRP as insoluble aggregates. This material was then dissolved in 6 M guanidine HCl prior to renaturation. For renaturation, the dissolved HRP was dialysed against 8 M urea, 50mM Tris HCl, 100mM NaCl for 24 hr. Ca^{2+} was then added (as $CaCl_2$) to 1 mM and the sample incubated for 2 hr at room temperature. This procedure resulted in the recovery of about 0.125% of the expected HRP activity by the standard pyrogallol colorimetric assay and based on the protein concentration and estimated purity of the preparation (see Table 1).

Table 1 - Renaturation of HRP Expressed in E. coli

Sample	Conditions	Rate of reaction (maximum) AU/min	Amount of recombinant HRP C assayed mcg	Activity AU/min mcg rec. HRP	Activity (% of max. activity of commercial HRP)
1	before 1st dialysis	0.01 AU/0.8 min	25 mcg	$5x10^{-3}$ AU/min mcg	0.007%
2	after 1st dialysis	0.015 AU/1.1 min	5.77 mcg	0.0024 AU/min mcg	0.034%
3	sample 2 incubated with 1 mM Ca^{2+} for 2h	0.01 AU/1.5 min	0.76 mcg	0.029 AU/min mcg	0.125%

Control samples prepared from similar cultures carrying the expression plasmid without the HRP gene gave backgrounds about 1000 fold less than this. The assay mixture contained freshly prepared pyrogallol and peroxide in the following concentrations: 11mM K phosphte, pH 6.0, 8mM H_2O_2, 0.55% w/v pyrogallol in H_2O. The HRP was added and the increase in adsorption at 420nm was followed.

Thus the synthetic HRP gene is capable of high level expression in E. coli and is capable of directing the synthesis of active product.

Example 4

The synthetic HRP gene of Example 2 was modified as follows to allow for its efficient expression in mammalian cells:

(a) The 3' end of the gene was extended from the Pst 1 site to include the C-terminal extension reported by Fujiyama et al. Eur. J. Biochem. **173,** 681-687 (1988).

(b) The 5' end of the gene was modified by the addition of a HindIII/HpaI linker which encoded a signal sequence based on an immunoglobulin signalpeptide.

The modified HRP gene is depicted in Figure 6, and will be referred to as HPRX.

Example 5

Expression of the Synthetic Horesradish Peroxidase Gene in Mammalian Cells

The HRPX gene of Example 4 was inserted into the mammlian cell expression vector pCPH11 to give pCP21, in which the HRP gene is expressed from the HCMV (Human Cytomegalovirus) early promoter, see Figure 7. The plasmid pCPH11 is based on pUC18, which is widely avaialble and from which it can be prepared by standard methods, using the information in Figure 7.

The HRP expression plasmid pCP21 was transfected into COS cells using the standard technique of calcium phosphate precipitation (20mcg DNA transfected per 10^6 cells). HRP activity was assayed in cell culture medium, 48-72h post transfection using tetra-methyl benzidine substrate (TMB), a standard HRP reagent. No HRP activity was detectable in control constructs which did not contain a signal sequence and/or the 3' extension. In contrast, HRP activity was clearly detectable in cells transfected with pCP21 (up to 10x greater than in controls). The results are shown in Table 2.

Table 2 - HRP Expression in COS Cells

Vol.Extract. (mcl)	O.D.450 Plasmid			
	pCP21	pCP22	pCP11	pCP12
100	.004	.022	.008	.003
50	.033	.012	.010	.013
25	.107*	.010	.003	.016
10	.084*	.011	.007	.017
5	.064*	.015	.012	.011
1	.028	.008	.007	.007

KEY

pCP21 HRP with N and C terminal signals, correct orientation.

pCP22 HRP with N and C terminal signals, wrong orientation.

pCP11 HRP with no signal sequences, correct orientation.

pCP12 HRP with no signal sequences, wrong orientation.

All results are the mean of duplicate samples.
* = significant level of activity.

HRP Assay

For assaying cell extracts, a substrate mix was prepared as follows:
TMB (3,3',5,5' tetramethyl benzidine (Sigma)) was dissolved to 10 mg/ml in DMSO and 100 mcl of this solution added to 100 ml of assay buffer (0.1M NaAc in citric acid, pH6.0) along with 100 mcl H_2O_2.

A cell extract was prepared by collecting the cells by centrifugation followed by freeze thawing or sonication. The medium, cell lysates and standards were aliquoted in 96 well microtitre plates as follows:

Sample	100	50	25	10	5	1	mcl
Assay Buffer	0	50	75	90	95	99	mcl

Blank samples were set up using 100 mcl of assay buffer alone. 100 mcl of TMB/H_2O_2 mix was added to the samples of incubated at RT for 30 mins to 1 hour. The reaction was stopped by the addition of 50

mcl of 2.5M H_2SO_4 and the colour change read at 450 nm on a plate reader.
Commercially available HRP was used as a standard diluted by a factor of 10^{-6}.

Claims

1. DNA coding for horseradish peroxidase and including the following sequence:

CAG TTA ACC CCT ACA TTC TAC GAC AAT AGC TGT CCC
AAC GTG TCC AAC ATC GTT CGC GAC ACA ATC GTC AAC
GAG CTC AGA TCC GAT CCC AGG ATC GCT GCT TCA ATA
TTA CGT CTG CAC TTC CAT GAC TGC TTC GTG AAT GGT
TGC GAC GCT AGC ATA TTA CTG GAC AAC ACC ACC AGT
TTC CGC ACT GAA AAG GAT GCA TTC GGG AAC GCT AAC
AGC GCC AGG GGC TTT CCA GTG ATC GAT CGC ATG AAG
GCT GCC GTT GAG TCA GCA TGC CCA CGA ACA GTC AGT
TGT GCA GAC CTG CTG ACT ATA GCT GCG CAA CAG AGC
GTG ACT CTT GCA GGC GGA CCG TCC TGG AGA GTG CCG
CTC GGT CGA CGT GAC TCC CTA CAG GCA TTC CTA GAT
CTG GCC AAC GCC AAC TTG CCT GCT CCA TTC TTC ACC
CTG CCC CAG CTG AAG GAT AGC TTT AGA AAC GTG GGT
CTG AAT CGC TCG AGT GAC CTT GTG GCT CTG TCC GGA
GGA CAC ACA TTT GGA AAG AAC CAG TGT AGG TTC ATC
ATG GAT AGG CTC TAC AAT TTC AGC AAC ACT GGG TTA
CCT GAC CCC ACG CTG AAC ACT ACG TAT CTC CAG ACA
CTG AGA GGC TTG TGC CCA CTG AAT GGC AAC CTC AGT
GCA CTA GTG GAC TTT GAT CTG CGG ACC CCA ACC ATC
TTC GAT AAC AAG TAC TAT GTG AAT CTA GAG GAG CAG
AAA GGC CTG ATA CAG AGT GAT CAA GAA CTG TTT AGC
AGT CCA AAC GCC ACT GAC ACC ATC CCA CTG GTG AGA
AGT TTT GCT AAC TCT ACT CAA ACC TTC TTT AAC GCC
TTC GTG GAA GCC ATG GAC CGT ATG GGT AAC ATT ACC
CCT CTG ACG GGT ACC CAA GGC CAG ATT CGT CTG AAC
TGC AGA GTG GTC AAC AGC AAC TCT

2. DNA as claimed in claim 1, further including, at the 5'end, flanking DNA having one of the following sequences:
AAGCTTAACCATG; or
AAGCTTCATATG;
or when the DNA is for expression in mammalian animals, the sequence:

AAGCTTCCACCATGAAGTGCTCCTGGGTGATCTTCTTCCTGATGGCCGTGGTGA-
CCGGCGTGAACTCC;

and, at the 3'end flanking DNA having the sequence:
TAATAAGGATCCGAATTC;
or, where the DNA is to be expressed in mammalian cells, the sequence:

CTACTCCATGATATGGTGGAGGTCGTTGACTTTGTTAGCTCTATGTAATAAGGA-
TCCGAATTC.

3. A genetic construct comprising DNA as claimed in claim 1 or claim 2.

4. A construct as claimed in claim 3, which is a vector.

5. A process for the preparation of DNA as claimed in claim 1 or claim 2, or a genetic construct in accordance with claim 3 or claim 4, the process comprising coupling successive nucleotides and/or ligating appropriate oligomers.

6. A construct as claimed in claim 3 or 4 comprising the sequence defined in claim 1 fused to any other sequence of DNA so as to result in a sequence capable of encoding a hybrid protein possessing peroxidase activity.

7. A construct as claimed in claim 6, wherein the other sequence of DNA is a gene encoding streptavidin or avidin such that the encoded fusion protein possesses both biotin binding and peroxidase activity.

8. A construct as claimed in claim 7, wherein the other sequence is a gene encoding an immunoglobulin-derived antigen binding function, such that the encoded fusion protein possesses both antigen binding and horseradish peroxidase activity.

9. A construct as claimed in claim 8, wherein the antigen binding function is an immunoglobulin heavy chain or light chain or fragments thereof or an engineered monomeric antigenic recognition site.

10. A construct as claimed in claim 4, which is an expression vector that provides for the co-expression of DNA as claimed in claim 1 or claim 2 and another gene of interest, either as a single fusion product, as a single polycistronic message or as two separate but linked transcriptional units.

11. A process for the production of a monodisperse horseradish peroxidase C comprising expression of a genetic construct as claimed in claim 3 or claim 4.

12. A set of oligonucleotides for the preparation of DNA as claimed in claim 1 or claim 2 comprising:




BB303
5' AGCTTAACTCGAGTGACCTTGTGGCTCTGTCCGGAGGACACACATTT GGAAGAACCA
3' ATTGAGCTCACTGGAACACCGAGACAGGCCTCCTGTGTGTAAACCTTCT TGGT
490 500 510 520 530 540
BB304
BB305
BB307
GTGTAGGTTCATCATGGATAGGCTCTACAA TTTCAGCAACACTGGGTTACCTGACCCCAC
CACATCCAAGTAGTACCTATCCGAGATGTTAAAGTCG TTGTGACCCAATGGACTGGGGTG
550 560 570 580 590 600
BB306
BB308
BB309
GCTGAACACTACGTA TCTCCAGACACTGAGAGGCTTGTGCCCACTGAATGGCAACCTC
CGACTTGTGATGCATAGAGGTC TGTGACTCTCCGAACACGGGTGACTTACCGTTGGAGTCACGTG
610 620 630 640 650 660
BB310
BB311
AGTGCACTAGTGGACTTTGATCTGCGGACCCCAACCATCTTCG ATAACAAGTACTATGTGAA
ATCACCTGAAACTAGACGCCTGGGGTTGGTAGAAGCTATTGTT CATGATACACTT
670 680 690 700 710 720
BB312
BB313
BB315
TCTAGAGGAGCAGAAAGGCCTGA TACAGAGTGATCAAGAACTGTTTAGCAGTCCAAACGC
AGATCTCCTCGTCTTTCCGGACTATGTCTC ACTAGTTCTTGACAAATCGTCAGGTTTGCG
730 740 750 760 770 780
BB314
BB316
BB317
CACTGA CACCATCCCACTGGTGAGAAGTTTTGCTAACTCTACTCAAA CCTTCTTTAACGC
GTGACTGTGGTAG GGTGACCACTCTTCAAAACGATTGAGATGAGTTTTGGAAGAA ATTGCG
790 800 810 820 830 840
BB318
BB319
BB321
CTTCGTGGAAGCCATGGACCGTATGGGTAACAT TACCCCTCTGACGGGTACCCAAGGCCA
GAAGCACCTTCGGTACCTGGCATACCCATTGTAATGGGGA GACTGCCCATGGGTTCCGGT
850 860 870 880 890 900
BB320
BB322
BB323
GATTCGTCTGAACTGC AGAGTGGTCAACAGCAACTCTTAATAAGGATCCG 3'
CTAAGCAGACTTGACGTCTCACC AGTTGTCGTTGAGAATTATTCCTAGGCTTAA 5'
910 920 930 940 950
BB324

Patentansprüche

1. DNA, die Meerrettich-Peroxidase codiert und die folgende Sequenz umfaßt:

```
CAG TTA ACC CCT ACA TTC TAC GAC AAT AGC TGT CCC
AAC GTG TCC AAC ATC GTT CGC GAC ACA ATC GTC AAC
GAG CTC AGA TCC GAT CCC AGG ATC GCT GCT TCA ATA
TTA CGT CTG CAC TTC CAT GAC TGC TTC GTG AAT GGT
TGC GAC GCT AGC ATA TTA CTG GAC AAC ACC ACC AGT
TTC CGC ACT GAA AAG GAT GCA TTC GGG AAC GCT AAC
AGC GCC AGG GGC TTT CCA GTG ATC GAT CGC ATG AAG
GCT GCC GTT GAG TCA GCA TGC CCA CGA ACA GTC AGT
TGT GCA GAC CTG CTG ACT ATA GCT GCG CAA CAG AGC
GTG ACT CTT GCA GGC GGA CCG TCC TGG AGA GTG CCG
CTC GGT CGA CGT GAC TCC CTA CAG GCA TTC CTA GAT
CTG GCC AAC GCC AAC TTG CCT GCT CCA TTC TTC ACC
CTG CCC CAG CTG AAG GAT AGC TTT AGA AAC GTG GGT
CTG AAT CGC TCG AGT GAC CTT GTG GCT CTG TCC GGA
GGA CAC ACA TTT GGA AAG AAC CAG TGT AGG TTC ATC
ATG GAT AGG CTC TAC AAT TTC AGC AAC ACT GGG TTA
CCT GAC CCC ACG CTG AAC ACT ACG TAT CTC CAG ACA
CTG AGA GGC TTG TGC CCA CTG AAT GGC AAC CTC AGT
GCA CTA GTG GAC TTT GAT CTG CGG ACC CCA ACC ATC
TTC GAT AAC AAG TAC TAT GTG AAT CTA GAG GAG CAG
AAA GGC CTG ATA CAG AGT GAT CAA GAA CTG TTT AGC
AGT CCA AAC GCC ACT GAC ACC ATC CCA CTG GTG AGA
AGT TTT GCT AAC TCT ACT CAA ACC TTC TTT AAC GCC
TTC GTG GAA GCC ATG GAC CGT ATG GGT AAC ATT ACC
CCT CTG ACG GGT ACC CAA GGC CAG ATT CGT CTG AAC
TGC AGA GTG GTC AAC AGC AAC TCT
```

2. DNA nach Anspruch 1, die zusätzlich am 5'-Ende flankierende DNA mit einer der folgenden Sequenzen umfaßt:
   AAGCTTAACCATG; oder
   AAGCTTCATATG;
   oder, wenn die DNA für die Expression in Säugerzellen eingesetzt wird, die Sequenz:

```
AAGCTTCCACCATGAAGTGCTCCTGGGTGATCTTCTTCCTGATGGCCGTGGTGA-
CCGGCGTGAACTCC;
```

und am 3'-Ende flankierende DNA mit der Sequenz:
TAATAAGGATCCGAATTC;
oder, wenn die DNA in Säugerzellen exprimiert werden soll, die Sequenz:

CTACTCCATGATATGGTGGAGGTCGTTGACTTTGTTAGCTCTATGTAATAAGGA-
TCCGAATTC.

3. Gentechnologisches Konstrukt, umfassend DNA nach Anspruch 1 oder 2.

4. Konstrukt nach Anspruch 3, nämlich ein Vektor.

5. Verfahren zur Herstellung von DNA nach Anspruch 1 oder 2, oder eines gentechnologischen Konstrukts nach Anspruch 3 oder 4, wobei das Verfahren die aufeinanderfolgende Kupplung von Nucleotiden und/oder die Ligierung geeigneter Oligomere umfaßt.

6. Konstrukt nach Anspruch 3 oder 4, umfassend die Sequenz gemäß der Definition in Anspruch 1, die mit einer anderen DNA-Sequenz fusioniert ist, so daß eine Sequenz erhalten wird, die ein Hybridprotein, das Peroxidaseaktivität besitzt, codieren kann.

7. Konstrukt nach Anspruch 6, wobei die andere DNA-Sequenz ein Gen ist, das Streptavidin oder Avidin codiert, so daß das codierte Fusionsprotein sowohl Biotinbindungsals auch Peroxidase-Aktivität besitzt.

8. Konstrukt nach Anspruch 7, wobei die andere Sequenz ein Gen ist, das eine von einem Immunglobulin stammende Antigenbindungsfunktion codiert, so daß das codierte Fusionsprotein sowohl Antigenbindungs- als auch Meerrettich-Peroxidase-Aktivität besitzt.

9. Konstrukt nach Anspruch 8, wobei die Antigenbindungsfunktion eine schwere oder leichte Immunglobulinkette oder Fragmente davon ist, oder eine konstruierte monomere Antigenerkennungsstelle.

10. Konstrukt nach Anspruch 4, nämlich ein Expressionsvektor, der die Coexpression von DNA nach Anspruch 1 oder 2 und eines anderen Gens von Interesse entweder als Einzelfusionsprodukt, als einzelne polycistronische Botschaft oder als zwei getrennte, aber verknüpfte Transkriptionseinheiten ermöglicht.

11. Verfahren zur Herstellung einer monodispersen Meerrettich-Peroxidase C, umfassend die Expression eines gentechnologischen Konstrukts nach Anspruch 3 oder 4.

12. Oligonucleotid-Set für die Herstellung von DNA nach Anspruch 1 oder 2, umfassend:




BB303
5'
3'
490
500
510
520
530
540
BB304
BB305
BB307
550
560
570
580
590
600
BB306
BB308
BB309
610
620
630
640
650
660
BB310
BB311
670
680
690
700
710
720
BB312
BB313
BB315
730
740
750
760
770
780
BB314
BB316
BB317
790
800
810
820
830
840
BB318
BB319
BB321
850
860
870
880
890
900
BB320
BB322
BB323
910
920
930
940
950
BB324

Revendications

1. ADN codant pour la peroxydase de raifort et comprenant la séquence suivante :

CAG TTA ACC CCT ACA TTC TAC GAC AAT AGC TGT CCC
AAC GTG TCC AAC ATC GTT CGC GAC ACA ATC GTC AAC
GAG CTC AGA TCC GAT CCC AGG ATC GCT GCT TCA ATA
TTA CGT CTG CAC TTC CAT GAC TGC TTC GTG AAT GGT
TGC GAC GCT AGC ATA TTA CTG GAC AAC ACC ACC AGT
TTC CGC ACT GAA AAG GAT GCA TTC GGG AAC GCT AAC
AGC GCC AGG GGC TTT CCA GTG ATC GAT CGC ATG AAG
GCT GCC GTT GAG TCA GCA TGC CCA CGA ACA GTC AGT
TGT GCA GAC CTG CTG ACT ATA GCT GCG CAA CAG AGC
GTG ACT CTT GCA GGC GGA CCG TCC TGG AGA GTG CCG
CTC GGT CGA CGT GAC TCC CTA CAG GCA TTC CTA GAT
CTG GCC AAC GCC AAC TTG CCT GCT CCA TTC TTC ACC
CTG CCC CAG CTG AAG GAT AGC TTT AGA AAC GTG GGT
CTG AAT CGC TCG AGT GAC CTT GTG GCT CTG TCC GGA
GGA CAC ACA TTT GGA AAG AAC CAG TGT AGG TTC ATC
ATG GAT AGG CTC TAC AAT TTC AGC AAC ACT GGG TTA
CCT GAC CCC ACG CTG AAC ACT ACG TAT CTC CAG ACA
CTG AGA GGC TTG TGC CCA CTG AAT GGC AAC CTC AGT
GCA CTA GTG GAC TTT GAT CTG CGG ACC CCA ACC ATC
TTC GAT AAC AAG TAC TAT GTG AAT CTA GAG GAG CAG
AAA GGC CTG ATA CAG AGT GAT CAA GAA CTG TTT AGC
AGT CCA AAC GCC ACT GAC ACC ATC CCA CTG GTG AGA
AGT TTT GCT AAC TCT ACT CAA ACC TTC TTT AAC GCC
TTC GTG GAA GCC ATG GAC CGT ATG GGT AAC ATT ACC
CCT CTG ACG GGT ACC CAA GGC CAG ATT CGT CTG AAC
TGC AGA GTG GTC AAC AGC AAC TCT

2. ADN tel que défini à la revendication 1, comprenant en outre, à l'extrémité 5', un ADN adjacent ayant l'une des séquences suivantes :
AAGCTTAACCATG ; ou
AAGCTTCATATG ;
ou, lorsque l'ADN est destiné à l'expression dans des cellules de mammifère, la séquence :

AAGCTTCCACCATGAAGTGCTCCTGGGTGATCTTCTTCCTGATGGCCGTGGTGA-
CCGGCGTGAACTCC ;

et, à l'extrémité 3', un ADN adjacent ayant la séquence :
TAATAAGGATCCGAATTC ;
ou, si l'ADN est destiné à être exprimé dans des cellules de mammifère, la séquence :

CTACTCCATGATATGGTGGAGGTCGTTGACTTTGTTAGCTCTATGTAATAAGGA-TCCGAATTC.

3. Produit de synthèse génétique comprenant l'ADN tel que défini à la revendication 1 ou à la revendication 2.

4. Produit de synthèse tel que défini à la revendication 3, qui est un vecteur.

5. Procédé de préparation de l'ADN tel que défini à la revendication 1 ou à la revendication 2, ou d'un produit de synthèse génétique tel que défini à la revendication 3 ou à la revendication 4, le procédé comprenant le couplage de nucléotides successifs et/ou la soudure d'oligomères appropriés.

6. Produit de synthèse selon la revendication 3 ou 4, comprenant la séquence telle que définie à la revendication 1, fusionnée à n'importe quelle autre séquence d'ADN, de façon à conduire à une séquence capable de coder pour une protéine hybride possédant l'activité peroxydase.

7. Produit de synthèse selon la revendication 6, dans lequel l'autre séquence d'ADN est un gène codant pour la streptavidine ou l'avidine, de telle sorte que la protéine de fusion codée possède à la fois l'activité de liaison à la biotine et l'activité peroxydase.

8. Produit de synthèse selon la revendication 7, dans lequel l'autre séquence est un gène codant pour une fonction de liaison à un antigène issu d'une immunoglobuline, de telle sorte que la protéine de fusion codée possède à la fois l'activité de liaison à un antigène et l'activité peroxydase de raifort.

9. Produit de synthèse selon la revendication 8, dans lequel la fonction de liaison à un antigène est une chaîne lourde ou une chaîne légère d'immunoglobuline, ou des fragments de celles-ci, ou un site de reconnaissance antigénique monomère obtenu par génie génétique.

10. Produit de synthèse selon la revendication 4, qui est un vecteur d'expression qui assure la co-expression de l'ADN tel que défini à la revendication 1 ou à la revendication 2 et d'un autre gène présentant un intérêt, soit sous la forme d'un produit de fusion unique, soit sous la forme d'un message polycistronique unique, soit sous la forme de deux unités de transcription séparées mais liées.

11. Procédé de fabrication d'une peroxydase de raifort C monodispersée, comprenant l'expression d'un produit de synthèse génétique tel que défini à la revendication 3 ou à la revendication 4.

12. Jeu d'oligonucléotides pour la préparation de l'ADN tel que défini à la revendication 1 ou à la revendication 2, comprenant :


BB279
BB280
BB281
BB282
BB283
BB284
BB285
BB286
BB287
BB288
BB289
BB290
BB291
BB292
BB293
BB294
BB295
BB296
BB297
BB298
BB299
BB300
BB301
BB302


BB303
BB304
BB305
BB306
BB307
BB308
BB309
BB310
BB311
BB312
BB313
BB314
BB315
BB316
BB317
BB318
BB319
BB320
BB321
BB322
BB323
BB324

FIGURE 1

AMINO ACID SEQUENCE OF HORSERADISH PEROXIDASE (INCLUDING INITIATOR METHIONINE).

(M) Q L T P T F Y D N S C P N V S N I V R
10 20

D T I V N E L R S D P R I A A S I L R L
30 40

H F H D C F V N G C D A S I L L D N T T
50 60

S F R T E K D A F G N A N S A R G F P V
70 80

I D R M K A A V E S A C P R T V S C A D
90 100

L L T I A A Q Q S V T L A G G P S W R V
110 120

P L G R R D S L Q A F L D L A N A N L P
130 140

A P F F T L P Q L K D S F R N V G L N R
150 160

S S D L V A L S G G H T F G K N Q C R F
170 180

I M D R L Y N F S N T G L P D P T L N T
190 200

T Y L Q T L R G L C P L N G N L S A L V
210 220

D F D L R T P T I F D N K Y Y V N L E E
230 240

Q K G L I Q S D Q E L F S S P N A T D T
250 260

I P L V R S F A N S T Q T F F N A F V E
270 280

A M D R M G N I T P L T G T Q G Q I R L
290 300

N C R V V N S N S
309

FIGURE 2a

SEQUENCE OF SYNTHETIC HORSERADISH PEROXIDASE GENE

```
          M  Q  L  T  P  T  F  Y  D  N  S  C  P  N  V  S  N
AAGCTTAACCATGCAGTTAACCCCTACATTCTACGACAATAGCTGTCCCAACGTGTCCAA
HinDIII      HpaI
TTCGAATTGGTACGTCAATTGGGGATGTAAGATGCTGTTATCGACAGGGTTGCACAGGTT
       10        20        30        40        50        60

 I  V  R  D  T  I  V  N  E  L  R  S  D  P  R  I  A  A  S  I
CATCGTTCGCGACACAATCGTCAACGAGCTCAGATCCGATCCCAGGATCGCTGCTTCAAT
     NruI              SacI                              SspI
GTAGCAAGCGCTGTGTTAGCAGTTGCTCGAGTCTAGGCTAGGGTCCTAGCGACGAAGTTA
       70        80        90       100       110       120

 L  R  L  H  F  H  D  C  F  V  N  G  C  D  A  S  I  L  L  D
ATTACGTCTGCACTTCCATGACTGCTTCGTGAATGGTTGCGACGCTAGCATATTACTGGA
                                          NheI
TAATGCAGACGTGAAGGTACTGACGAAGCACTTACCAACGCTGCGATCGTATAATGACCT
      130       140       150       160       170       180

 N  T  T  S  F  R  T  E  K  D  A  F  G  N  A  N  S  A  R  G
CAACACCACCAGTTTCCGCACTGAAAAGGATGCATTCGGGAACGCTAACAGCGCCAGGGG
                    NsiI
GTTGTGGTGGTCAAAGGCGTGACTTTTCCTACGTAAGCCCTTGCGATTGTCGCGGTCCCC
      190       200       210       220       230       240

 F  P  V  I  D  R  M  K  A  A  V  E  S  A  C  P  R  T  V  S
CTTTCCAGTGATCGATCGCATGAAGGCTGCCGTTGAGTCAGCATGCCCACGAACAGTCAG
       ClaI/PvuI                    SphI
GAAAGGTCACTAGCTAGCGTACTTCCGACGGCAACTCAGTCGTACGGGTGCTTGTCAGTC
      250       260       270       280       290       300

 C  A  D  L  L  T  I  A  A  Q  Q  S  V  T  L  A  G  G  P  S
TTGTGCAGACCTGCTGACTATAGCTGCGCAACAGAGCGTGACTCTTGCAGGCGGACCGTC
      BspMI          FspI                          RsrII
AACACGTCTGGACGACTGATATCGACGCGTTGTCTCGCACTGAGAACGTCCGCCTGGCAG
      310       320       330       340       350       360

 W  R  V  P  L  G  R  R  D  S  L  Q  A  F  L  D  L  A  N  A
CTGGAGAGTGCCGCTCGGTCGACGTGACTCCCTACAGGCATTCCTAGATCTGGCCAACGC
                SalI                          BglII/BalI
GACCTCTCACGGCGAGCCAGCTGCACTGAGGGATGTCCGTAAGGATCTAGACCGGTTGCG
      370       380       390       400       410       420

 N  L  P  A  P  F  F  T  L  P  Q  L  K  D  S  F  R  N  V  G
CAACTTGCCTGCTCCATTCTTCACCCTGCCCCAGCTGAAGGATAGCTTTAGAAACGTGGG
                          PvuII
GTTGAACGGACGAGGTAAGAAGTGGGACGGGGTCGACTTCCTATCGAAATCTTTGCACCC
      430       440       450       460       470       480

 L  N  R  S  S  D  L  V  A  L  S  G  G  H  T  F  G  K  N  Q
TCTGAATCGCTCGAGTGACCTTGTGGCTCTGTCCGGAGGACACACATTTGGAAAGAACCA
       XhoI                    BspMII
AGACTTAGCGAGCTCACTGGAACACCGAGACAGGCCTCCTGTGTGTAAACCTTTCTTGGT
      490       500       510       520       530       540
```


C R F I M D R L Y N F S N T G L P D P T
GTGTAGGTTCATCATGGATAGGCTCTACAATTTCAGCAACACTGGGTTACCTGACCCCAC
BstEII
CACATCCAAGTAGTACCTATCCGAGATGTTAAAGTCGTTGTGACCCAATGGACTGGGGTG
550 560 570 580 590 600
L N T T Y L Q T L R G L C P L N G N L S
GCTGAACACTACGTATCTCCAGACACTGAGAGGCTTGTGCCCACTGAATGGCAACCTCAG
SnaBI PflMI
CGACTTGTGATGCATAGAGGTCTGTGACTCTCCGAACACGGGTGACTTACCGTTGGAGTC
610 620 630 640 650 660
A L V D F D L R T P T I F D N K Y Y V N
TGCACTAGTGGACTTTGATCTGCGGACCCCAACCATCTTCGATAACAAGTACTATGTGAA
ApaLI/SpeI ScaI
ACGTGATCACCTGAAACTAGACGCCTGGGGTTGGTAGAAGCTATTGTTCATGATACACTT
670 680 690 700 710 720
L E E Q K G L I Q S D Q E L F S S P N A
TCTAGAGGAGCAGAAAGGCCTGATACAGAGTGATCAAGAACTGTTTAGCAGTCCAAACGC
XbaI StuI BclI
AGATCTCCTCGTCTTTCCGGACTATGTCTCACTAGTTCTTGACAAATCGTCAGGTTTGCG
730 740 750 760 770 780
T D T I P L V R S F A N S T Q T F F N A
CACTGACACCATCCCACTGGTGAGAAGTTTTGCTAACTCTACTCAAACCTTCTTTAACGC
BstXI
GTGACTGTGGTAGGGTGACCACTCTTCAAAACGATTGAGATGAGTTTGGAAGAAATTGCG
790 800 810 820 830 840
F V E A M D R M G N I T P L T G T Q G Q
CTTCGTGGAAGCCATGGACCGTATGGGTAACATTACCCCTCTGACGGGTACCCAAGGCCA
NcoI KpnI
GAAGCACCTTCGGTACCTGGCATACCCATTGTAATGGGGAGACTGCCCATGGGTTCCGGT
850 860 870 880 890 900
I R L N C R V V N S N S * *
GATTCGTCTGAACTGCAGAGTGGTCAACAGCAACTCTTAATAAGGATCCGAATTC
PstI BamHI EcoRI
CTAAGCAGACTTGACGTCTCACCAGTTGTCGTTGAGAATTATTCCTAGGCTTAAG
910 920 930 940 950

FIGURE 2b
SUMMARY OF USEFUL RESTRICTION SITES.

ENZYME	SEQUENCE	POSITION
HinDIII	AAGCTT	1
HpaI	GTTAAC	16
SacI	GAGCTC	86
SspI	AATATT	118
NheI	GCTAGC	164
NsiI	ATGCAT	210
ClaI	ATCGAT	251
PvuI	CGATCG	253
SphI	GCATGC	281
BspMI	ACCTGC	309
FspI	TGCGCA	325
RsrII	CGGACCG	352
SalI	GTCGAC	378
BglII	AGATCT	406
BalI	TGGCCA	411
PvuII	CAGCTG	452
XhoI	CTCGAG	490
BspMII	TCCGGA	512
BstEII	GGTTACC	585
SnaBI	TACGTA	610
PflMI	CCACTGAATGG	641
ApaLI	GTGCAC	660
SpeI	ACTAGT	664
ScaI	AGTACT	708
XbaI	TCTAGA	721
StuI	AGGCCT	736
BclI	TGATCA	751
BstXI	CCATCCCACTGG	789
NcoI	CCATGG	852
KpnI	GGTACC	887
PstI	CTGCAG	913
BamHI	GGATCC	944
EcoRI	GAATTC	950

FIGURE 2c

SEQUENCE OF SYNTHETIC HORSERADISH PEROXIDASE GENE 5' END HALF

```
          M  Q  L  T  P  T  F  Y  D  N  S  C  P  N  V  S  N
AAGCTTAACCATGCAGTTAACCCCTACATTCTACGACAATAGCTGTCCCAACGTGTCCAA
HinDIII        HpaI
TTCGAATTGGTACGTCAATTGGGGATGTAAGATGCTGTTATCGACAGGGTTGCACAGGTT
       10        20        30        40        50        60

  I  V  R  D  T  I  V  N  E  L  R  S  D  P  R  I  A  A  S  I
CATCGTTCGCGACACAATCGTCAACGAGCTCAGATCCGATCCCAGGATCGCTGCTTCAAT
     NruI                 SacI                              SspI
GTAGCAAGCGCTGTGTTAGCAGTTGCTCGAGTCTAGGCTAGGGTCCTAGCGACGAAGTTA
       70        80        90       100       110       120

  L  R  L  H  F  H  D  C  F  V  N  G  C  D  A  S  I  L  L  D
ATTACGTCTGCACTTCCATGACTGCTTCGTGAATGGTTGCGACGCTAGCATATTACTGGA
                                              NheI
TAATGCAGACGTGAAGGTACTGACGAAGCACTTACCAACGCTGCGATCGTATAATGACCT
      130       140       150       160       170       180

  N  T  T  S  F  R  T  E  K  D  A  F  G  N  A  N  S  A  R  G
CAACACCACCAGTTTCCGCACTGAAAAGGATGCATTCGGGAACGCTAACAGCGCCAGGGG
                        NsiI
GTTGTGGTGGTCAAAGGCGTGACTTTTCCTACGTAAGCCCTTGCGATTGTCGCGGTCCCC
      190       200       210       220       230       240

  F  P  V  I  D  R  M  K  A  A  V  E  S  A  C  P  R  T  V  S
CTTTCCAGTGATCGATCGCATGAAGGCTGCCGTTGAGTCAGCATGCCCACGAACAGTCAG
         ClaI/PvuI                       SphI
GAAAGGTCACTAGCTAGCGGTACTTCCGACGGCAACTCAGTCGTACGGGTGCTTGTCAGTC
      250       260       270       280       290       300

  C  A  D  L  L  T  I  A  A  Q  Q  S  V  T  L  A  G  G  P  S
TTGTGCAGACCTGCTGACTATAGCTGCGCAACAGAGCGTGACTCTTGCAGGCGGACCGTC
       BspMI           FspI                          RsrII
AACACGTCTGGACGACTGATATCGACGCGTTGTCTCGCACTGAGAACGTCCGCCTGGCAG
      310       320       330       340       350       360

  W  R  V  P  L  G  R  R  D  S  L  Q  A  F  L  D  L  A  N  A
CTGGAGAGTGCCGCTCGGTCGACGTGACTCCCTACAGGCATTCCTAGATCTGGCCAACGC
                 SalI                              BglII/BalI
GACCTCTCACGGCGAGCCAGCTGCACTGAGGGATGTCCGTAAGGATCTAGACCGGTTGCG
      370       380       390       400       410       420

  N  L  P  A  P  F  F  T  L  P  Q  L  K  D  S  F  R  N  V  G
CAACTTGCCTGCTCCATTCTTCACCCTGCCCCAGCTGAAGGATAGCTTTAGAAACGTGGG
                                 PvuII
GTTGAACGGACGAGGTAAGAAGTGGGACGGGGTCGACTTCCTATCGAAATCTTTGCACCC
      430       440       450       460       470       480

  L  N  R  S
TCTGAATCGCTCGAGGAATTC
        XhoI  EcoRI
AGACTTAGCGAGCTCCTTAAG
      490
```

FIGURE 2d

SEQUENCE OF SYNTHETIC HORSERADISH PEROXIDASE GENE 3' END HALF.

```
            S  S  D  L  V  A  L  S  G  G  H  T  F  G  K  N  Q
  AAGCTTAACTCGAGTGACCTTGTGGCTCTGTCCGGAGGACACACATTTGGAAAGAACCA
 HinDIII  XhoI                        BspMII
  TTCGAATTGAGCTCACTGGAACACCGAGACAGGCCTCCTGTGTGTAAACCTTTCTTGGT
        490        500        510        520        530        540

   C  R  F  I  M  D  R  L  Y  N  F  S  N  T  G  L  P  D  P  T
 GTGTAGGTTCATCATGGATAGGCTCTACAATTTCAGCAACACTGGGTTACCTGACCCCAC
                                                BstEII
 CACATCCAAGTAGTACCTATCCGAGATGTTAAAGTCGTTGTGACCCAATGGACTGGGGTG
        550        560        570        580        590        600

   L  N  T  T  Y  L  Q  T  L  R  G  L  C  P  L  N  G  N  L  S
 GCTGAACACTACGTATCTCCAGACACTGAGAGGCTTGTGCCCACTGAATGGCAACCTCAG
          SnaBI                                 PflMI
 CGACTTGTGATGCATAGAGGTCTGTGACTCTCCGAACACGGGTGACTTACCGTTGGAGTC
        610        620        630        640        650        660

   A  L  V  D  F  D  L  R  T  P  T  I  F  D  N  K  Y  Y  V  N
 TGCACTAGTGGACTTTGATCTGCGGACCCCAACCATCTTCGATAACAAGTACTATGTGAA
ApaLI/SpeI                                              ScaI
 ACGTGATCACCTGAAACTAGACGCCTGGGGTTGGTAGAAGCTATTGTTCATGATACACTT
        670        680        690        700        710        720

   L  E  E  Q  K  G  L  I  Q  S  D  Q  E  L  F  S  S  P  N  A
 TCTAGAGGAGCAGAAAGGCCTGATACAGAGTGATCAAGAACTGTTTAGCAGTCCAAACGC
 XbaI             StuI              BclI
 AGATCTCCTCGTCTTTCCGGACTATGTCTCACTAGTTCTTGACAAATCGTCAGGTTTGCG
        730        740        750        760        770        780

   T  D  T  I  P  L  V  R  S  F  A  N  S  T  Q  T  F  F  N  A
 CACTGACACCATCCCACTGGTGAGAAGTTTTGCTAACTCTACTCAAACCTTCTTTAACGC
          BstXI
 GTGACTGTGGTAGGGTGACCACTCTTCAAAACGATTGAGATGAGTTTGGAAGAAATTGCG
        790        800        810        820        830        840

   F  V  E  A  M  D  R  M  G  N  I  T  P  L  T  G  T  Q  G  Q
 CTTCGTGGAAGCCATGGACCGTATGGGTAACATTACCCCTCTGACGGGTACCCAAGGCCA
            NcoI                                        KpnI
 GAAGCACCTTCGGTACCTGGCATACCCATTGTAATGGGGAGACTGCCCATGGGTTCCGGT
        850        860        870        880        890        900

   I  R  L  N  C  R  V  V  N  S  N  S  *  *
 GATTCGTCTGAACTGCAGAGTGGTCAACAGCAACTCTTAATAAGGATCCGAATTC
             PstI                                BamHI EcoRI
 CTAAGCAGACTTGACGTCTCACCAGTTGTCGTTGAGAATTATTCCTAGGCTTAAG
        910        920        930        940        950
```

FIGURE 3a

DESIGN OF OLIGOMERS FOR SYNTHETIC HORSERADISH PEROXIDASE GENE 5'HALF.



FIGURE 3b

DESIGN OF OLIGOMERS FOR SYNTHETIC HORSERADISH PEROXIDASE GENE 3' HALF.



FIGURE 4a

SUMMARY OF ASSEMBLY PROCEDURE, 5′ HALF.

a) kinased oligomers annealed in pairs and mixed in two groups (A & B).



b) oligomers ligated together in two groups. (BB279 and BB302 not kinased to avoid multimerisation.



c) The ligations were checked for the presence of fragment A & B on 2% agarose gels then the ligation reactions were mixed and the reaction allowed to continue to give the final product.



d) The HRP gene fragment was isolated on a 2% LGT agarose gel and cloned into EcoRI/HinDIII cut pUC18.



v = vector sequence
p = 5′ phosphates

FIGURE 4b

SUMMARY OF ASSEMBLY PROCEDURE, 3' HALF.

a) kinased oligomers annealed in pairs and mixed in two groups (A & B).



b) oligomers ligated together in two groups. (BB303 and BB324 not kinased to avoid multimerisation.



c) The ligations were checked for the presence of fragment C & D on 2% agarose gels then the ligation reactions were mixed and the reaction allowed to continue to give the final product.



d) The HRP gene fragment was isolated on a 2% LGT agarose gel and cloned into EcoRI/HinDIII cut pUC18



v = vector sequence
p = 5' phoshates

FIGURE 4c

SUMMARY OF FINAL ASSEMBLY PROCEDURE.

a) 5′ and 3′ clones of HRP cloned in pUC18 were digested with XhoI and EcoRI. Relevant fragments from each digest were isolated from a 0.8% LGT agarose gel.





b) XhoI/EcoRI fragment carrying 3′ half of HRP ligated into XhoI/EcoRI cut HRP 5′ half clone.



c) Completed gene cloned in pUC18.



v = vector sequence

Figure 5. The HRP Expression Plasmid pSD18.



Figure 6. Synthetic HRP Gene Modified for Expression in Mammalian Cells.

```
            M  k  c  s  w  v  i  f  f  l  m  a  v  v  t  g  v
AAGCTTCCACCATGAAGTGCTCCTGGGTGATCTTCTTCCTGATGGCCGTGGTGACCGGCG
         10         20         30         40         50         60

   n  s<>Q  L  T  P  T  F  Y  D  N  S  C  P  N  V  S  N  I  V
TGAACTCCCAGTTAACCCCTACATTCTACGACAATAGCTGTCCCAACGTGTCCAACATCG
         70HpaI     80         90        100        110        120

   R  D  T  I  V  N  E  L  R  S  D  P  R  I  A  A  S  I  L  R
TTCGCGACACAATCGTCAACGAGCTCAGATCCGATCCCAGGATCGCTGCTTCAATATTAC
       130        140        150        160        170        180

   L  H  F  H  D  C  F  V  N  G  C  D  A  S  I  L  L  D  N  T
GTCTGCACTTCCATGACTGCTTCGTGAATGGTTGCGACGCTAGCATATTACTGGACAACA
       190        200        210        220        230        240

   T  S  F  R  T  E  K  D  A  F  G  N  A  N  S  A  R  G  F  P
CCACCAGTTTCCGCACTGAAAAGGATGCATTCGGGAACGCTAACAGCGCCAGGGGCTTTC
       250        260        270        280        290        300

   V  I  D  R  M  K  A  A  V  E  S  A  C  P  R  T  V  S  C  A
CAGTGATCGATCGCATGAAGGCTGCCGTTGAGTCAGCATGCCCACGAACAGTCAGTTGTG
       310        320        330        340        350        360

   D  L  L  T  I  A  A  Q  Q  S  V  T  L  A  G  G  P  S  W  R
CAGACCTGCTGACTATAGCTGCGCAACAGAGCGTGACTCTTGCAGGCGGACCGTCCTGGA
       370        380        390        400        410        420

   V  P  L  G  R  R  D  S  L  Q  A  F  L  D  L  A  N  A  N  L
GAGTGCCGCTCGGTCGACGTGACTCCCTACAGGCATTCCTAGATCTGGCCAACGCCAACT
       430        440        450        460        470        480

   P  A  P  F  F  T  L  P  Q  L  K  D  S  F  R  N  V  G  L  N
TGCCTGCTCCATTCTTCACCCTGCCCCAGCTGAAGGATAGCTTTAGAAACGTGGGTCTGA
       490        500        510        520        530        540

   R  S  S  D  L  V  A  L  S  G  G  H  T  F  G  K  N  Q  C  R
ATCGCTCGAGTGACCTTGTGGCTCTGTCCGGAGGACACACATTTGGAAAGAACCAGTGTA
       550        560        570        580        590        600

   F  I  M  D  R  L  Y  N  F  S  N  T  G  L  P  D  P  T  L  N
GGTTCATCATGGATAGGCTCTACAATTTCAGCAACACTGGGTTACCTGACCCCACGCTGA
       610        620        630        640        650        660

   T  T  Y  L  Q  T  L  R  G  L  C  P  L  N  G  N  L  S  A  L
ACACTACGTATCTCCAGACACTGAGAGGCTTGTGCCCACTGAATGGCAACCTCAGTGCAC
       670        680        690        700        710        720
```

```
   V  D  F  D  L  R  T  P  T  I  F  D  N  K  Y  Y  V  N  L  E
TAGTGGACTTTGATCTGCGGACCCCAACCATCTTCGATAACAAGTACTATGTGAATCTAG
       730        740        750        760        770        780

   E  Q  K  G  L  I  Q  S  D  Q  E  L  F  S  S  P  N  A  T  D
AGGAGCAGAAAGGCCTGATACAGAGTGATCAAGAACTGTTTAGCAGTCCAAACGCCACTG
       790        800        810        820        830        840

   T  I  P  L  V  R  S  F  A  N  S  T  Q  T  F  F  N  A  F  V
ACACCATCCCACTGGTGAGAAGTTTTGCTAACTCTACTCAAACCTTCTTTAACGCCTTCG
       850        860        870        880        890        900

   E  A  M  D  R  M  G  N  I  T  P  L  T  G  T  Q  G  Q  I  R
TGGAAGCCATGGACCGTATGGGTAACATTACCCCTCTGACGGGTACCCAAGGCCAGATTC
       910        920        930        940        950        960

   L  N  C  R  V  V  N  S  N  S  l  l  h  d  m  v  e  v  v  d
GTCTGAACTGCAGAGTGGTCAACAGCAACTCTCTACTCCATGATATGGTGGAGGTCGTTG
      PstI        980        990       1000       1010       1020

   f  v  s  s  m  *  *
ACTTTGTTAGCTCTATGTAATAAGGATCCGAATTC
      1030       1040         EcoRI
```

KEY

Underlined sequences indicate linkers used to adapt synthetic gene.

Lower case residues indicate N and C terminal pre & pro sequences.

Figure 7. The HRP Expression Plasmid pCP21.